| Q35883166 | 5-year follow-up of a randomized controlled trial of immediate versus delayed zoledronic acid for the prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen: N03CC (Alliance) trial |
| Q36997869 | A highly sensitive prenylation assay reveals in vivo effects of bisphosphonate drug on the Rab prenylome of macrophages outside the skeleton |
| Q35870578 | A meta-analysis of the antitumor effect and safety of bisphosphonates in the treatment of multiple myeloma |
| Q88646725 | A phase II study evaluating the efficacy of zoledronic acid in prevention of aromatase inhibitor-associated musculoskeletal symptoms: the ZAP trial |
| Q50229125 | A phase III multicenter, randomized, controlled study of combined androgen blockade with versus without zoledronic acid in prostate cancer patients with metastatic bone disease: results of the ZAPCA trial |
| Q51741445 | Adjuvant Bisphosphonate Therapy in Postmenopausal Breast Cancer. |
| Q30982699 | Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials |
| Q26781435 | Adjuvant bisphosphonates in patients with breast cancer: does the potency matter? |
| Q91733167 | Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial |
| Q38230839 | Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trial |
| Q37418209 | Adjuvant zoledronic acid therapy for patients with early stage breast cancer: an updated systematic review and meta-analysis |
| Q33920919 | Anti-Tumor Activity and Immunotherapeutic Potential of a Bisphosphonate Prodrug |
| Q90398992 | Antiresorptive agents' bone-protective and adjuvant effects in postmenopausal women with early breast cancer |
| Q36207662 | Are adjuvant bisphosphonates now standard of care of women with early stage breast cancer? A debate from the Canadian Bone and the Oncologist New Updates meeting |
| Q90672793 | Aromatase inhibitor therapy in recurrent, estrogen-receptor positive uterine serous carcinoma: A case report |
| Q30275126 | Aromatase inhibitor-induced bone loss increases the progression of estrogen receptor-negative breast cancer in bone and exacerbates muscle weakness in vivo |
| Q35832193 | Basal and therapy-driven hypoxia-inducible factor-1α confers resistance to endocrine therapy in estrogen receptor-positive breast cancer |
| Q38147841 | Beyond aspirin-cancer prevention with statins, metformin and bisphosphonates |
| Q38137763 | Bisphosphonate-related osteonecrosis of the jaw in patients with breast cancer |
| Q47693752 | Bisphosphonates and other bone agents for breast cancer. |
| Q26795493 | Bisphosphonates as anticancer agents in early breast cancer: preclinical and clinical evidence |
| Q38205707 | Bisphosphonates in the management of thalassemia-associated osteoporosis: a systematic review of randomised controlled trials |
| Q34752876 | Bisphosphonates inactivate human EGFRs to exert antitumor actions |
| Q85651592 | Bisphosphonates, bone, and breast cancer recurrence |
| Q35750472 | Bone Health in Patients with Breast Cancer: Recommendations from an Evidence-Based Canadian Guideline |
| Q91517674 | Bone Metastasis: Find Your Niche and Fit in |
| Q39157481 | Bone Modifier Use as Adjuvant Therapy for Early Breast Cancer |
| Q51760058 | Bone health during endocrine therapy for cancer. |
| Q35531006 | Bone remodeling markers and bone metastases: From cancer research to clinical implications |
| Q37337487 | Bone targeted treatments in cancer - The story so far |
| Q64980540 | Bone-Modifying Agents in Early-Stage and Advanced Breast Cancer. |
| Q28081294 | Bone-Targeted Therapy |
| Q57117791 | Breast cancer |
| Q35066907 | Breast cancer and osteoporosis - management of cancer treatment-induced bone loss in postmenopausal women with breast cancer |
| Q89986604 | Breast cancer outcome in relation to bone mineral density and bisphosphonate use: a sub-study of the DATA trial |
| Q85273053 | Breast cancer: Zoledronic acid--more than just a bone drug |
| Q35750453 | Can Zoledronic Acid be Beneficial for Promoting Tumor Response in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy? |
| Q49211720 | Cancer Treatment and Bone Health |
| Q55322511 | Cancer Treatment-Induced Bone Loss in Women With Breast Cancer and Men With Prostate Cancer. |
| Q35632616 | Cancer Treatment-Induced Bone Loss in women with breast cancer |
| Q53080443 | Changes in bone mineral density at 3 years in postmenopausal women receiving anastrozole and risedronate in the IBIS-II bone substudy: an international, double-blind, randomised, placebo-controlled trial. |
| Q91989244 | Clinical benefits of bone targeted agents in early breast cancer |
| Q26752834 | Clinical utility of letrozole in the treatment of breast cancer: a Chinese perspective |
| Q35441390 | Comparative effectiveness on survival of zoledronic acid versus pamidronate in multiple myeloma |
| Q37127038 | Comparison of γδ T cell responses and farnesyl diphosphate synthase inhibition in tumor cells pretreated with zoledronic acid. |
| Q33775316 | Correlation of mammographic density and serum calcium levels in patients with primary breast cancer |
| Q39927095 | Cost-effectiveness of dual-energy X-ray absorptiometry plus antiresorptive treatment in Australian women with breast cancer who receive aromatase inhibitors. |
| Q35934290 | Cost-utility of adjuvant zoledronic acid in patients with breast cancer and low estrogen levels |
| Q85289735 | Denosumab and fracture risk in women with breast cancer |
| Q59798450 | Denosumab versus zoledronic acid for preventing symptomatic skeletal events in Asian postmenopausal women with oestrogen-receptor-positive advanced breast cancer: an outcome analyses with a mean follow-up of 3 years |
| Q57290351 | Density functional theory studies on a non-covalent interaction system: hydrogen-bonded dimers of zoledronate |
| Q91741515 | Development and validation of a novel nomogram for predicting distant metastasis-free survival among breast cancer patients |
| Q92289321 | Dichotomic effects of clinically used drugs on tumor growth, bone remodeling and pain management |
| Q36925557 | Different prognostic value of circulating and disseminated tumor cells in primary breast cancer: Influence of bisphosphonate intake? |
| Q36290007 | Dosing of zoledronic acid with its anti-tumor effects in breast cancer |
| Q35431110 | Effect of bisphosphonate use on risk of postmenopausal breast cancer: results from the randomized clinical trials of alendronate and zoledronic acid |
| Q34581699 | Effects of zoledronic acid and the association between its efficacy and γδT cells in postmenopausal women with breast cancer treated with preoperative hormonal therapy: a study protocol |
| Q87247237 | Effects of zoledronic acid on bone mineral density in premenopausal women receiving neoadjuvant or adjuvant therapies for HR+ breast cancer: the ProBONE II study |
| Q38216322 | Endocrine aspects of bone metastases |
| Q42363605 | Estradiol impairs the antiproliferative and proapoptotic effect of Zoledronic acid in hormone sensitive breast cancer cells in vitro. |
| Q50070694 | Evaluation and management of skeletal disease in cancer care |
| Q58795240 | Exposure to alendronate is associated with a lower risk of bone metastases in osteoporotic women with early breast cancer |
| Q36414483 | Human stromal cells are required for an anti-breast cancer effect of zoledronic acid |
| Q36204083 | Immune modulation of CD4(+)CD25(+) regulatory T cells by zoledronic acid |
| Q52670810 | Incidence, risk factors and prognostic characteristics of bone metastases and skeletal-related events (SREs) in breast cancer patients: A systematic review of the real world data. |
| Q37135281 | Italian association of clinical endocrinologists (AME) position statement: drug therapy of osteoporosis. |
| Q36491450 | JBO-Launched and flying ahead |
| Q38406796 | Long-term effect of aromatase inhibitors on bone microarchitecture and macroarchitecture in non-osteoporotic postmenopausal women with breast cancer |
| Q37390319 | Long-term remission after multiple bone metastases following cervical cancer: A case report |
| Q38123680 | Luminal breast cancer: from biology to treatment |
| Q49836028 | MRONJ risk of adjuvant bisphosphonates in early stage breast cancer |
| Q89533515 | Management manual for cancer treatment-induced bone loss (CTIBL): position statement of the JSBMR |
| Q37742180 | Management of Aromatase Inhibitor-Associated Bone Loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: Joint position statement of the IOF, CABS, ECTS, IEG, ESCEO IMS, and SIOG |
| Q38090917 | Management of cancer treatment-induced bone loss |
| Q37043903 | Mechanisms of action of bisphosphonates in oncology: a scientific concept evolving from antiresorptive to anticancer activities |
| Q64981225 | Neoadjuvant zoledronic acid for HER2-positive breast cancer: the Zo-NAnTax trial. |
| Q34906361 | Novel immunostimulatory effects of osteoclasts and macrophages on human γδ T cells. |
| Q38818271 | Oestrogen receptor positive breast cancer metastasis to bone: inhibition by targeting the bone microenvironment in vivo. |
| Q48207269 | Osteoclast inhibition in postmenopausal breast cancer: Is the evidence too strong to ignore? |
| Q27008336 | Osteonecrosis of the jaw during biyearly treatment with zoledronic acid for aromatase inhibitor associated bone loss in early breast cancer: A literature review |
| Q37198504 | Osteoporosis and cancer |
| Q57108686 | Osteoporosis and musculoskeletal complications related to therapy of breast cancer |
| Q37577433 | Panobinostat synergizes with zoledronic acid in prostate cancer and multiple myeloma models by increasing ROS and modulating mevalonate and p38-MAPK pathways. |
| Q30543788 | Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013 |
| Q26746212 | Pharmacologic management of bone-related complications and bone metastases in postmenopausal women with hormone receptor-positive breast cancer |
| Q36491479 | Possible survival benefits from zoledronic acid treatment in patients with bone metastases from solid tumours and poor prognostic features-An exploratory analysis of placebo-controlled trials |
| Q55384058 | Prevalence of Medication-Related Osteonecrosis of the Jaw in Patients with Breast Cancer, Prostate Cancer, and Multiple Myeloma. |
| Q26775765 | Prevention and treatment of bone fragility in cancer patient |
| Q35667318 | Prevention of Bone Metastases in Breast Cancer Patients. Therapeutic Perspectives |
| Q34967135 | Probenecid as a sensitizer of bisphosphonate-mediated effects in breast cancer cells |
| Q28551320 | Randomized Controlled Trial of Zoledronic Acid plus Chemotherapy versus Chemotherapy Alone as Neoadjuvant Treatment of HER2-Negative Primary Breast Cancer (JONIE Study) |
| Q34945422 | Real-time intravital imaging establishes tumor-associated macrophages as the extraskeletal target of bisphosphonate action in cancer |
| Q36677418 | Reimbursement for bone loss prevention is different between women with breast cancer and men with prostate cancer: time for a revision |
| Q47110989 | Reproductive hormone analyses and effects of adjuvant zoledronic acid in early breast cancer - An AZURE (BIG 01/04) sub-study |
| Q34752800 | Repurposing of bisphosphonates for the prevention and therapy of nonsmall cell lung and breast cancer |
| Q90706168 | Retrospective study on the efficacy of bisphosphonates in tyrosine kinase inhibitor-treated patients with non-small cell lung cancer exhibiting bone metastasis |
| Q40554954 | Risk of hospitalisation and death due to bone fractures after breast cancer: a registry-based cohort study |
| Q37475161 | SEOM Clinical Guideline for bone metastases from solid tumours (2016). |
| Q34779663 | Survival benefit of zoledronic Acid in postmenopausal breast cancer patients receiving aromatase inhibitors |
| Q96645540 | Survival in older women with early stage breast cancer receiving low-dose bisphosphonates or denosumab |
| Q34042715 | Targeted and Osteo-Oncologic Treatment in Early Breast Cancer: What Is State-of-the-Art and What Might Become so within the Next 5 Years? |
| Q38736342 | Targeting Cancer Cells with a Bisphosphonate Prodrug. |
| Q36187063 | The Frequency of and Risk Factors for the Use of Bisphosphonates in the Adjuvant Setting of Primary Breast Cancer in Germany |
| Q89314569 | The Osteoclast in Bone Metastasis: Player and Target |
| Q33920055 | The best of both worlds - managing the cancer, saving the bone |
| Q33772299 | The microenvironment matters: estrogen deficiency fuels cancer bone metastases |
| Q35667196 | Treatment and Prevention of Bone Metastases from Breast Cancer: A Comprehensive Review of Evidence for Clinical Practice |
| Q97426733 | Tumor dormancy in bone |
| Q49178710 | Vertebral fractures among breast cancer survivors in China: a cross-sectional study of prevalence and health services gaps. |
| Q26849473 | Where Do Bone-Targeted Agents RANK in Breast Cancer Treatment? |
| Q37684242 | Zoledronic acid alters hematopoiesis and generates breast tumor-suppressive bone marrow cells. |
| Q64099099 | Zoledronic acid blocks the interaction between breast cancer cells and regulatory T-cells |